Donchida Srimuan

Chulalongkorn University — Thailand

Medicine · Health Sciences

15h-index713citations47works4.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(39), COVID-19 Clinical Research Studies(24), Animal Virus Infections Studies(17), Bacterial Infections and Vaccines(7), Immunotherapy and Immune Responses(6)

Publications47 total

Seroprevalence of antibodies against diphtheria, tetanus, and pertussis across various age groups during the post-COVID-19 pandemic period in Chonburi Province, Thailand
Heliyon·2024· 7 citedOpen Access
Persistence of hepatitis B surface antibody until 7 years of age following administration of hexavalent and pentavalent vaccines in children at 2, 4, 6, and 18 months
Vaccine X·2024Open Access
Persistence of Antibodies against Measles, Mumps, and Rubella after the Two-Dose MMR Vaccination: A 7-Year Follow-Up Study
Vaccines·2024· 4 citedOpen Access
Antibody persistence to diphtheria toxoid, tetanus toxoid, <i>Bordetella pertussis</i> antigens, and <i>Haemophilus influenzae</i> type b following primary and first booster with pentavalent versus hexavalent vaccines
Human Vaccines & Immunotherapeutics·2024· 6 citedOpen Access
Long-Term Dynamic Changes in Hybrid Immunity over Six Months after Inactivated and Adenoviral Vector Vaccination in Individuals with Previous SARS-CoV-2 Infection
Vaccines·2024· 5 citedOpen Access
Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
Heliyon·2023· 6 citedOpen Access
Epidemiology and clinical characteristics of severe acute respiratory infections among hospitalized children under 5 years of age in a tertiary care center in Bangkok, Thailand, 2019–2020
Heliyon·2023· 11 citedOpen Access
Seroprevalence of SARS-CoV-2 anti-nucleocapsid total Ig, anti-RBD IgG antibodies, and infection in Thailand: a cross-sectional survey from October 2022 to January 2023
Scientific Reports·2023· 15 citedOpen Access
Dynamics of Cytokine, SARS-CoV-2-Specific IgG, and Neutralizing Antibody Levels in COVID-19 Patients Treated with Convalescent Plasma
Diseases·2023· 5 citedOpen Access
SARS-CoV-2 Antibody Dynamics after COVID-19 Vaccination and Infection: A Real-World Cross-Sectional Analysis
Vaccines·2023· 12 citedOpen Access
Neutralizing antibodies against Omicron BA.5 among children with infection alone, vaccination alone, and hybrid immunity
International Journal of Infectious Diseases·2023· 8 citedOpen Access
Immunogenicity of the pentavalent DTwP-HB-Hib vaccine (Shan-5) used in the Thai Expanded Program on Immunization compared to the hexavalent DTaP-HB-Hib-IPV and DTwP-HB-Hib (Quinvaxem) vaccines administered to infants at 2, 4, 6 months of age
Vaccine·2023· 12 cited
Comparison of the reactogenicity and immunogenicity between two‐dose mRNA COVID‐19 vaccine and inactivated COVID‐19 vaccine followed by an mRNA vaccine in children aged 5−11 years
Journal of Medical Virology·2023· 4 cited
SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during the pre- and omicron-dominant wave, from January 2021 through December 2022, Thailand: A longitudinal study
PLoS ONE·2023· 17 citedOpen Access
The Fourth Dose of mRNA COVID-19 Vaccine Following 12 Different Three-Dose Regimens: Safety and Immunogenicity to Omicron BA.4/BA.5
Vaccines·2023· 7 citedOpen Access
The fourth dose of mRNA COVID-19 vaccine following 12 different three-dose regimens: Safety and immunogenicity to Omicron BA.4/BA.5
2023· 4 citedOpen Access
SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during pre- and omicron-dominant wave, from January 2021 through November 2022, Thailand: Longitudinal study
2022· 1 citedOpen Access
Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3 to 4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
2022· 2 citedOpen Access
Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens
International Journal of Infectious Diseases·2022· 19 citedOpen Access
Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated followed by an mRNA vaccine in children aged 5 - 11 years
2022Open Access
page 1 of 3Next →

Frequent Co-authors

Yong Poovorawan(47), Nasamon Wanlapakorn(46), Preeyaporn Vichaiwattana(39), Thanunrat Thongmee(39), Sitthichai Kanokudom(36), Suvichada Assawakosri(36), Nungruthai Suntronwong(36), Natthinee Sudhinaraset(35), Thaksaporn Thatsanatorn(30), Sirapa Klinfueng(30), Pornjarim Nilyanimit(28), Chompoonut Auphimai(27), Ritthideach Yorsaeng(26), Jira Chansaenroj(26), Thaneeya Duangchinda(17), Warangkana Chantima(17), Pattarakul Pakchotanon(17), Thaksaporn Thatsanathorn(15), Sittisak Honsawek(14), Juthathip Mongkolsapaya(11)